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Abstract
Background: One-dimensional (1D) 1H nuclear magnetic resonance (NMR) spectroscopy is
widely used in metabolomic studies involving biofluids and tissue extracts. There are several
software packages that support compound identification and quantification via 1D 1H NMR by
spectral fitting techniques. Because 1D 1H NMR spectra are characterized by extensive peak
overlap or spectral congestion, two-dimensional (2D) NMR, with its increased spectral resolution,
could potentially improve and even automate compound identification or quantification. However,
the lack of dedicated software for this purpose significantly restricts the application of 2D NMR
methods to most metabolomic studies.
Results: We describe a standalone graphics software tool, called MetaboMiner, which can be used
to automatically or semi-automatically identify metabolites in complex biofluids from 2D NMR
spectra. MetaboMiner is able to handle both 1H-1H total correlation spectroscopy (TOCSY) and
1H-13C heteronuclear single quantum correlation (HSQC) data. It identifies compounds by
comparing 2D spectral patterns in the NMR spectrum of the biofluid mixture with specially
constructed libraries containing reference spectra of ~500 pure compounds. Tests using a variety
of synthetic and real spectra of compound mixtures showed that MetaboMiner is able to identify
>80% of detectable metabolites from good quality NMR spectra.
Conclusion: MetaboMiner is a freely available, easy-to-use, NMR-based metabolomics tool that
facilitates automatic peak processing, rapid compound identification, and facile spectrum
annotation from either 2D TOCSY or HSQC spectra. Using comprehensive reference libraries
coupled with robust algorithms for peak matching and compound identification, the program
greatly simplifies the process of metabolite identification in complex 2D NMR spectra.
Background
Metabolomics is a rapidly-growing field of "-omics"
research concerned with the high-throughput compari-
son, identification and quantification of large numbers of
metabolites in biological systems [1]. Metabolomics only
became possible as a result of recent technology break-
throughs in small molecule separation, identification and
quantification. These include advances in ultra-sensitive,
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ultra-precise mass spectrometry (MS), robotic, multi-
dimensional NMR spectroscopy, and greatly improved
HPLC and UPLC separation technologies [2]. While other
techniques may be more sensitive or less expensive, NMR
has emerged as an ideal platform for studying metabolites
in biofluids. It is a rapid, highly precise, non-destructive,
and quantitative technique that allows one to compare,
identify and quantify a wide range of compounds without
the need for prior compound separation or derivatization
[3-6]. NMR is particularly amenable to compounds that
are less tractable to GC-MS or LC-MS analysis, such as sug-
ars, amines, volatile ketones and relatively non-reactive
compounds. A key disadvantage of NMR is that it is a rel-
atively insensitive technique, with a lower limit of detec-
tion of 1~5 μM and a requirement of relatively large
sample sizes (~500 μL).
Currently, most NMR-based metabolomic studies involve
the analysis of 1D 1H NMR spectra, although 1D 13C and
31P NMR spectra may also be analyzed [7-10]. There are
generally two routes to analyzing NMR spectra for metab-
olomic studies. In one method (called the chemometric
approach), the compounds are not initially identified –
only their spectral patterns and intensities are recorded
and statistically compared in order to identify the relevant
spectral features that distinguish sample classes. Once
these features have been located, a variety of approaches
may then be used to identify the corresponding metabo-
lites [11]. In the other approach (often called quantitative
metabolomics or targeted profiling), compounds are first
identified and quantified by comparing the NMR spec-
trum of the biofluid of interest to a spectral reference
library obtained from pure compounds [12]. Once these
compounds are identified and quantified, the data can be
analyzed in many different ways to identify the most rele-
vant biomarkers or informative pathways.
A variety of protocols and software tools have been
recently developed for conducting quantitative metabo-
lomics via 1D 1H NMR [5,6,12,13]. In most cases, a man-
ual peak-fitting process is required in order to perform
compound identification and quantification. However,
this manual fitting process can become particularly diffi-
cult and prone to frequent errors, especially for very com-
plex biofluid mixtures (such as urine or tissue extracts)
due to severe spectral overlap. In contrast to 1D NMR, 2D
NMR offers a robust approach to resolving excessively
overlapped spectra. Indeed 2D (and 3D) NMR has long
been used to resolve and identify individual resonances
from large macromolecules such as DNA, RNA and pro-
teins. 2D NMR experiments such as TOCSY, HSQC and J-
resolved spectroscopy are also increasingly being used in
metabolomic studies in order to resolve spectral ambigu-
ities to aid in the identification of specific compounds in
complex biofluid mixtures [14-22].
A number of small-molecule NMR databases have been
developed in recent years to support metabolomics
research, including the Human Metabolome Database
(HMDB) [23], the BioMagResBank Database (BMRB)
[24], the Madison Metabolomics Consortium Database
(MMCD) [25], the Magnetic Resonance Metabolomics
Database (MRMD) [26], and the Platform for RIKEN
Metabolomics (PRIMe). These resources, which contain
significant numbers of reference NMR spectra of metabo-
lites, also support metabolite identification through web-
based submission of 1D and 2D NMR peak lists. How-
ever, these on-line tools don't generally provide graphical
support for peak filtering, processing, comparative display
or annotation. Furthermore, they don't exploit additional
constraints such as knowledge about biofluid composi-
tion or metabolite concentration ranges to make com-
pound identification even more robust, more accurate,
and more efficient. We propose that by using a compre-
hensive 2D spectral reference library along with a more
detailed knowledge of metabolite compositions of differ-
ent biofluids, it is possible to greatly improve compound
identification from 2D NMR spectra. Here we report our
efforts in developing an easy-to-use, graphically-based,
stand-alone software tool, called MetaboMiner, to per-
form semi-automated metabolite identification from 2D
TOCSY and HSQC-spectra of complex biofluid mixtures.
Methods
Data Collection and Curation
Key to the development of this software package was the
creation of an extensive 2D spectral library containing
TOCSY and HSQC spectra of pure metabolites. We used
several publicly available sources in constructing this
library. The majority of the raw 1H-1H TOCSY spectra were
collected from the standard compound spectral library
available at the BMRB database [24]. A few additional
compound spectra were obtained from the MRMD [26].
The 1H-13C HSQC spectral library was downloaded from
the HMDB [23]. These raw spectra contained a number of
spectral artefacts (noise, water bands, asymmetries, peaks
from TSP or DSS, contaminants, etc.). Consequently it was
necessary to convert these raw spectra into "synthetic" or
"simplified" spectra corresponding to the peaks specific to
the pure compounds of interest. This conversion was
done manually, with each of these simplified, noise-free
spectra being examined for inconsistencies by comparing
them to the original raw spectra and the compound's
known resonance assignments. In total, the MetaboMiner
TOCSY reference library includes spectra from 223 com-
mon metabolites and the MetaboMiner HSQC library
contains spectra from 502 metabolites. The compounds
in both libraries were further catalogued into three sub-
libraries corresponding to the three common human
biofluids – cerebrospinal fluid (CSF), plasma and urine.
The classification was based on their respective metabolicBMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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compositions listed in the HMDB [23]. Since the presence
of these biofluid-specific metabolites was determined by a
variety of technologies not limited to NMR, we further
investigated the appearance of these metabolites in a large
number of 1D 1H spectra collected from CSF, plasma and
urine. The combined collection of compounds (and spec-
tra) were used to create corresponding "common
biofluid" 2D NMR spectral libraries that effectively repre-
sent a generic biofluid or cell extract. The "CSF", "plasma",
"urine", "biofluid" and "total" spectral libraries are stored
as XML files and are editable via MetaboMiner's graphical
user interface (GUI).
After the spectral libraries were constructed, each peak for
each compound in each library was assigned a series of
uniqueness values that are specific for that reference
library. A unique peak in MetaboMiner is defined as a rel-
atively isolated peak around which no peak from any
other compound is observed based on the spectral library
of the given biofluid. For any given peak, its uniqueness
value is calculated as the total number of surrounding
peaks from other compounds within a given chemical
shift "distance". Five distance levels were used to measure
peak uniqueness. For 1H chemical shifts, the distance
thresholds are 0.01, 0.02, 0.03, 0.04, and 0.05 ppm. For
13C chemical shifts, the distance thresholds are set at 0.05,
0.10, 0.15, 0.20, and 0.25 ppm. For instance, an HSQC
peak with a series of assigned uniqueness values of 0-0-0-
1-2 indicates that no peak from any other compound in
the reference library is observed within 0.03 ppm (1H
dimension) and 0.15 ppm (13C dimension) of that peak.
It also indicates that one peak from another compound in
the spectra library was observed within 0.03~0.04 ppm
(1H dimension) and 0.15~0.20 ppm (13C dimension) and
another peak from another compound was observed
within 0.04~0.05 ppm (1H dimension) and 0.20~0.25
ppm (13C dimension). See Figure 1 for a more complete
description of the uniqueness value concept. These
uniqueness values are automatically updated after any
spectral library change using MetaboMiner's graphical
user interface.
Peak Processing, Peak Matching and Compound 
Identification
As part of its input, MetaboMiner requires peak lists corre-
sponding to the peaks that were identified in either the
TOCSY or HSQC spectra collected from the biofluid(s) of
interest. While it is possible for users to provide manually
picked peak lists, MetaboMiner also supports processing
of multidimensional NMR peak lists obtained from auto-
matic peak peaking programs. Multidimensional NMR
spectra typically contain substantial numbers of spectral
artefacts such as baseline distortions, intense solvent lines,
ridges, sinc wiggles, etc. Automatic peak-picking programs
tend to mistake these noise signals for real resonances.
Therefore, any raw 2D spectra collected from biofluids
must be processed appropriately before attempting to
match them to MetaboMiner's reference spectral library.
Two automated procedures were found to be very effective
in cleaning up raw 2D spectra: 1) streak removal and 2)
symmetrical editing. Note that the latter processing tech-
nique is only applicable for TOCSY spectra. Spectral
streaks are usually caused by residual solvent signals (i.e.
water) or the presence of other compounds at extremely
high concentrations. Streaks can be recognized by their
specific locations and prominent shapes in the NMR spec-
tra. Streak removal was implemented by searching for
groups of peaks at these common locations and eliminat-
ing them from the peak list. Symmetrical editing exploits
the fact that real TOCSY peak signals form a symmetrical
square pattern along the diagonal line. Off-diagonal peaks
without any corresponding symmetrical peaks can be con-
sidered to be artefacts. Both peak positions and intensities
(if provided by the user) of the corresponding peaks are
examined for symmetry. Since TOCSY cross peaks are fre-
An illustration of the calculation of uniqueness values Figure 1
An illustration of the calculation of uniqueness val-
ues. The red peak represents the peak of interest and three 
peaks are in its immediate vicinity. The calculations are only 
performed at five chemical shifts distance levels – 0.01, 0.02, 
0.03, 0.04, 0.05 ppm along the 1H dimension, and 0.05, 0.10, 
0.15, 0.20, 0.25 ppm along the 13C dimension. No peak is 
observed in the first three distance levels. So the maximum 
unique scope for this peak is (0.03, 0.15) ppm. Peak A is 
found within 0.03~0.04 ppm (1H dimension) and 0.15~0.20 
ppm (13C dimension) of the red peak; Peak B is found within 
0.04~0.05 ppm (1H dimension) and 0.20~0.25 ppm (13C 
dimension) of the red peak; Peak C is not considered since 
the chemical shift distance is more than 0.05 ppm along the 
1H dimension. Therefore, the assigned uniqueness values are 
0-0-0-1-2. Note that the distance is not drawn to scale.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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quently not of equal intensity we require that the intensity
ratio between the upper and lower-diagonal peaks should
be within a range of 0.8~2.5 of each other to be consid-
ered symmetrical.
In order to accommodate small chemical shift differences
between the observed NMR spectra and the reference
NMR spectra, an adaptive threshold method was imple-
mented based on the uniqueness values (described
above) of each reference peak. During the peak searching/
matching process, the search threshold varies automati-
cally based on the maximum uniqueness value of the cur-
rent peak. For instance, when searching for potential
matches for a TOCSY peak with uniqueness values of 0-0-
0-0-1, MetaboMiner will automatically set its threshold to
0.04 ppm. The peak matching and adaptive thresholding
employ two processes: a reverse search strategy and a for-
ward search strategy. In the reverse search strategy, the
library peaks are searched and matched against the query
peaks. Typically most query peaks find their potential
matches during this reverse search step. However there are
usually some peaks left without any matches. In order to
assign these unmatched peaks a forward search is per-
formed in which the unmatched query peaks are searched
against the reference library with expanded thresholds –
0.08 ppm for TOCSY and 0.12 ppm (1H) and 0.4 ppm
(13C) for HSQC spectra. A match is identified if only a sin-
gle reference peak is identified within this range.
In MetaboMiner a compound is considered to be present
only if its matched pattern satisfies the requirements of
what we call "minimal signatures". A minimal signature is
defined as the minimum peak set that can uniquely iden-
tify a compound from all others in a given spectral library.
Based on the complete peak set of the reference spectral
library, many minimal signatures can be derived through
different combinations of unique peaks. A single peak
match may be considered a minimal signature if it is com-
pletely unique. More peaks are required to define a mini-
mal signature for less unique ones. For instance, in our
current implementation, the presence of a single peak
with uniqueness values 0-0-0-0-x (x >= 0) will determine
the presence of the corresponding compound (subject to
authenticity checks as discussed later); while at least two
peaks with uniqueness values 0-0-0-x-x are required to
reach the decision.
Since query spectra (i.e. real spectra from biofluids) usu-
ally contain substantial levels of spectral noise, even after
pre-processing, we found that we could reduce MetaboM-
iner's false positive rate even further by implementing sev-
eral authenticity checks. These include: 1) having a
minimum number of matched peaks (3 for TOCSY spec-
tra and 1 for HSQC spectra), 2) having a minimum
matched fraction of peaks (1/2 for TOCSY spectra and 1/
6 for HSQC spectra), 3) ensuring the presence of certain
peaks for certain compounds (determined by manual test-
ing and validation for each compound), and 4) ensuring
that the identified compounds were known to be in a
given biofluid.
User Interface Description
MetaboMiner's graphical user interface was implemented
using Java Swing technology. The spectral visualization
and manipulation tools were built using the JGraph
library (Java open source graph visualization library,
http://www.jgraph.com). Figure 2 illustrates a flowchart
describing the MetaboMiner GUI. There are four main
functional views, 1) a Processing View, 2) a Search View,
3) an Annotation View, and 4) a Library View. All these
views share the same component arrangement, with pan-
els on the right side being used for visualizing and manip-
ulating peaks, and the panels on the left being used for
displaying parameters, compound lists, structure images,
etc. Navigation to each view is readily accessible by click-
ing an appropriate menu item.
When the program launches, the default view is the
"Processing View" where users can copy and paste the
automatically picked peak list. The input format must be
either a two or three-column list, with numbers separated
by a space or a semicolon. The first two columns must be
the x and y chemical shift coordinates of each peak in the
2D spectrum and the optional third column must be the
peak height or peak intensity. After processing the raw
peaks, both the original and the processed spectra will be
displayed on MetaboMiner's spectral viewing panel
(located on the right). With this viewing panel, users can
directly edit peaks on the spectrum if necessary. For man-
ually picked peaks, this step can be skipped by turning the
processing options off. By clicking the "Search" button,
MetaboMiner's "Search View" will be displayed with its
initial, automated compound identification results. Users
can adjust the search threshold or switch the reference
library to further refine the result. A compound is marked
as identified if the matched pattern passes the authenticity
checks and satisfies the minimum signature requirement.
The raw matched scores are also displayed. MetaboM-
iner's interface allows users to visually inspect the
matched peaks of any metabolite against the correspond-
ing reference spectrum. By right clicking any peak dis-
played on the spectrum, users can search the library for
this particular peak. The identified compound list can be
saved in three different formats by clicking the "Export"
button. A screenshot of MetaboMiner's "Search View" is
shown in Figure 3.
Users can further refine the automated search results by
manually annotating the raw 2D spectrum. By clicking the
"Refine" button in the "Search View", the "AnnotationBMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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View" will be launched with the identified compounds
being transferred as the starting point. Users can also
directly enter the "Annotation View" mode by clicking the
"Annotate" button from the "Console" menu. In order to
perform manual annotation, users first need to load a
high resolution spectral image in PNG format and set up
the spectral axes properly. Peak searching is performed by
right clicking the peak position on the spectrum to search
the reference library as shown in Figure 4. All compounds
that generate peaks within the search threshold will be
checked. The compound with the closest peak match will
be highlighted with its database reference spectrum dis-
played on the uploaded "raw" spectrum. Users can per-
form peak annotation for any currently displayed
compound. Double clicking any database peak will open
a small text editor where users can enter the peak assign-
ment or a comment. The peak pattern of the identified
compounds can also be edited to match the experimental
spectrum. For example, users can insert, delete, or drag a
database peak to match the observed peak in the raw spec-
MetaboMiner flowchart Figure 2
MetaboMiner flowchart. The query peaks obtained from an automatic peak-picking program are first processed to remove 
streaks and other artefacts. The cleaned peak list is then scanned for the presence of peak patterns of compounds in a spectral 
reference library corresponding to the biofluid that has been identified by the user. Spectral images can be used to further 
refine the search result.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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trum. These changes will be valid only for the current ses-
sion. To make permanent changes, MetaboMiner's
"Library View" must be used.
The "Library View" is intended for browsing and manag-
ing MetaboMiner's spectral libraries. To view all the avail-
able reference spectra in MetaboMiner's libraries, users
must click the "Browse" button in the "Library" menu.
Double clicking any compound in the compound list will
open a popup window for peak editing. Any changes will
be reflected on the spectrum at real time. New compounds
can be introduced by clicking the "New" button at the bot-
tom of the compound list. A new compound can be either
exported from another library or be created from scratch
through the wizard dialog. Both peak editing or adding
new compounds will trigger updating of the uniqueness
values of the affected peaks. For researchers who study
other types of biological samples (e.g. plant or microbial
extracts), they may either use MetaboMiner's generic spec-
tral reference library or create a new library customized for
that particular type of biofluid. Library creation or dele-
tion can be easily accomplished by clicking the appropri-
ate menu items in the "Library" menu. The compounds in
the default reference library are linked to PubChem,
HMDB [18], and the BMRB [19] via the hyperlink under
their structure icon. The "Graphics" menu enables users to
change the size, shape, or color of the synthetic peaks to
suit their preferences.
It is important to note that MetaboMiner does not support
spectral processing such as phasing, baseline correction or
chemical shift referencing. There are many other high-
Screenshot of MetaboMiner's "Search View" Figure 3
Screenshot of MetaboMiner's "Search View". The left panel shows the library compounds that have matches in the 
query peaks. The selected checkbox indicates the corresponding compound is considered to be present by MetaboMiner. 'R' 
or 'F' indicates whether the compound is identified during the reverse search or forward search, respectively. On the right 
panel, the reference peaks (in red) of the current selected compound is displayed with query peaks as background. The color 
variations represent the peak intensities with the dark green corresponding to the strongest peak intensities. When the mouse 
is placed over any synthetic peak, all its information (name, position, uniqueness values, etc.) will be displayed on the view panel. 
Right clicking on any peak will allow users to search the spectral library for this particular peak.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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quality NMR-processing software available for this task,
including NMRPipe [27], Felix (Molecular Simulations,
Inc., San Diego, CA), VNMR (Varian, Inc., Palo Alto, CA),
and XWinNMR (Bruker Analytik GmbH, Karlsruhe, Ger-
many), to name a few. These tools should be used prior to
loading spectral images into MetaboMiner. In other
words, MetaboMiner is not a spectral processing tool, but
a NMR-based metabolomics tool that facilitates auto-
matic peak processing, rapid compound identification,
and facile spectrum annotation capabilities through an
intuitive graphical interface. MetaboMiner is available at:
http://wishart.biology.ualberta.ca/metabominer/
Evaluation protocol
MetaboMiner was assessed in a variety of ways using both
synthetic and experimental NMR spectra. The synthetic
spectra were generated from the 162 compounds that
have both TOCSY and HSQC spectra in the reference
library. The experimental spectra were collected from
three defined compound mixtures (totalling 72 com-
pounds) and a biofluid sample of known composition
(plasma). These evaluations allowed a complete and com-
prehensive assessment of MetaboMiner's performance as
well as its potential strengths and limitations.
The effects of different types of spectral noise on 
compound identification
The performance of the minimal signature method and
the adaptive threshold method were evaluated under two
common types of spectral noise – missing peaks and
"drifting" peaks (i.e. peaks that have drifted from their
canonical positions due to temperature, pH or solvent
effects). The missing peaks were simulated by deleting
peaks of each compound at random with 0%, 10%, 20%,
Screenshot of MetaboMiner's "Annotation View" Figure 4
Screenshot of MetaboMiner's "Annotation View". The contents of the reference spectral library and the automatically 
identified compound list are shown on the left panel. The spectral image is displayed on the right panel. The red peaks corre-
spond to the reference spectra of the current compound being annotated (Valine). Peak searching is carried out by right click-
ing on a corresponding Valine peak. The user can also directly edit the current compound by inserting, removing, or dragging 
its peaks to match the exact pattern of the reference spectrum.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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30%, 40%, 50% probabilities. The chemical shift drift
effects were simulated by adding random values of ± 0.01,
± 0.02, ± 0.03, ± 0.04, ± 0.05 ppm for each 1H chemical
shift, and ± 0.05, ± 0.10, ± 0.15, ± 0.20, ± 0.25 ppm for
each  13C chemical shift. The spectra of each synthetic
query mixture were generated by first pooling the peaks
from 50 compounds that were randomly selected from
the MetaboMiner reference spectral library (162 com-
pounds). After introducing this artificial spectral noise,
the query mixtures were searched against the reference
spectral library with and without using the adaptive
threshold method. Two compound identification strate-
gies were compared – the minimal signature method
(MS) and the percentage match method (PM) with 75%
as the cut-off value. The F-measure was used for perform-
ance evaluation, where F = 2 × (precision × recall)/(precision
+ recall) where recall is the proportion of true positives in
the returned result (recall = TP/(TP+FN)) and precision is
a measure of the percentage of positive or correct results
(precision = TP/(TP+FP)). The values were obtained as the
averages of TOCSY and HSQC search results over 50 iter-
ations. Figure 5A summarizes MetaboMiner's perform-
ance using data with different fractions of missing peaks.
Figure 5B shows the results using data with increasing
chemical shift drift effects.
The effects of different spectral data types on compound 
identification
We further investigated the usefulness of different NMR
data types for compound identification based on our con-
cept of a minimal spectral signature. Four NMR data types
were compared – 1D 1H, 1D 13C, 1H TOCSY, and 1H-13C
HSQC spectra. For this particular evaluation, reference 1D
1H and 1D 13C spectra were obtained from the corre-
sponding  1H and 13C chemical shifts of MetaboMiner's
HSQC spectral library. For a small number of com-
pounds, these artificial 1D spectra lacked some of the
expected 1H or 13C signals that might be seen in a real 1D
NMR spectrum, but their absence also helped to simulate
the fact that some peaks in 1D NMR spectra are broadened
or washed out due to signal overlap or solvent suppres-
sion.
Synthetic 2D NMR spectra (query spectra) representing
different biofluids of increasing molecular complexity
were generated by pooling peaks of 20, 30, 40, 50, 60, 70,
and 80 compounds randomly selected from MetaboM-
iner's reference spectral library. To further simulate noise
or pH/salt effects, 10% of the peaks from the query spectra
were deleted at random, followed by the introduction of
random chemical shift changes (± 0.01 ppm for 1H and ±
0.05 ppm for 13C) to the remaining peaks. The resulting
peaks were subsequently searched against MetaboMiner's
reference spectral library using the adaptive threshold
Comparative performance of different search strategies Figure 5
Comparative performance of different search strategies. Synthetic mixture query spectra were generated by pooling 
the peaks of 50 randomly selected compounds from MetaboMiner's reference spectral library. Different levels of spectral noise 
were added to these peaks and then compounds were identified with (*) and without using the adaptive threshold method. 
The Figure 5A, the query peaks were deleted at random with 0%, 10%, 20%, 30%, 40% and 50% probabilities; Figure 5B, the 
query peaks were subject to five levels of random chemical shift variations (± 0.01, ± 0.02, ± 0.03, ± 0.04, ± 0.05 ppm for each 
1H chemical shift, and ± 0.05, ± 0.10, ± 0.15, ± 0.20, ± 0.25 ppm for each 13C chemical shift). The F scores were averaged over 
50 iterations. (Abbreviations: PM, percentage match method; MS, minimal signature method).BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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method. The F measures were averaged over 50 iterations.
The result is summarized in Figure 6.
Compound identification using experimental spectra
Twelve 2D NMR experiments (six TOCSY and six HSQC)
were collected under different pH conditions using three
synthetic mixtures and a plasma sample. The three syn-
thetic mixtures were composed of 27, 21, and 24 common
metabolites, respectively, with concentrations ranging
from 40 to 60 mM. The plasma sample contained 35 iden-
tifiable metabolites (ranging in concentration from 0.1 to
10 mM) as determined by independent profiling of its 1D
1H NMR spectra by several experienced individuals using
Chenomx's NMR Suite software [12]. These results were
further confirmed by spiking/doping authentic standards
into the plasma sample and by GC-MS analysis. The
plasma sample was prepared by filtering the sample
through a 3 kDa filter (to remove proteins), then lyophi-
lizing and finally dissolving the remaining solids in dis-
tilled water to its 1/5 original volume. Deuterium oxide
(D2O) was added to make a final concentration of 90%
H2O and 10% D2O. All spectra were acquired at 25°C. Six
spectra were collected on a Varian INOVA 800 MHz spec-
trometer equipped with a 5 mm triple axis gradient cryo-
probe. The other six spectra were collected on a Varian
INOVA 500 MHz spectrometer with a 5 mm triple-reso-
nance z-gradient probe. The TOCSY experiments were per-
formed using the wgtocsy pulse sequence, and the HSQC
experiments were performed using the gChsqc pulse
sequence, both provided by Varian's BioPack. For the
TOCSY experiments, the spectral width was set to 11990
Hz and a mixing time of 50 milliseconds. Sixteen tran-
sients were collected for each of 128 t1 intervals using an
acquisition time of 0.085 seconds and a relaxation delay
of 2.0 seconds. The total acqisition time for the TOCSY
spectra was 2.5 hours For the 13C-HSQC experiments, the
spectral widths of the proton and carbon dimensions were
11990 Hz and 28160 Hz respectively. Sixty four transients
were acquired for each t1 interval using an acquisition
time of 0.085 seconds and a relaxation delay of 1.0 sec-
onds. The spectra were collected with 2048*256 complex
points for the 1H and 13C dimensions respectively. The
total spectral acquisition time for the HSQC spectra was 5
hours. Sample TOCSY and HSQC spectra are available
[see Additional File 1].
The raw NMR spectra were first processed using NMRPipe
[27] and the peaks were subsequently picked using
Sparky's [28] automatic peak picking program. The result-
ing "raw" peak lists were copied and pasted to the process-
ing view of MetaboMiner. Both peak processing and
compound identification were performed using Metabo-
Miner's default parameter sets. The reference library used
for the synthetic mixtures was the biofluid (common)
library. For plasma data, the plasma (common) library
was used. To assess the degradation in performance
assuming no prior knowledge of the sample source (urine,
plasma, cell extract or generic biofluid) the complete spec-
tral reference library (223 compounds for TOCSY, 502
compounds for HSQC) was also used to identify com-
pounds. To assess the performance of the web-servers that
support 2D NMR mixture analysis – the HMDB [23], the
MMCD [25], the BMRB [24], and the SpinAssign [29] of
PRIMe http://prime.psc.riken.jp/ – the same set of peak
lists were submitted. For PRIMe, the default search param-
eters were used. For other web services, the search thresh-
old for 1H was set to 0.03 ppm and 0.10 ppm for 13C. The
results are summarized in Tables 1 and 2.
Results
Using synthetic query spectra constructed as described
previously, the performance characteristics of MetaboM-
iner were first assessed under different levels of spectral
noise. Secondly, the utility of different NMR data types
were also investigated for our approach of compound
identification. Finally, we evaluated MetaboMiner's per-
formance using a total of 12 real NMR spectra collected
from defined compound mixtures and a plasma sample of
known composition.
After creating the spectral reference libraries and calculat-
ing the uniqueness values for each peak, we first investi-
Evaluation of MetaboMiner using simulated datasets Figure 6
Evaluation of MetaboMiner using simulated datasets. 
Synthetic mixture query spectra were generated by pooling 
peaks from 20, 30, 40, 50, 60, 70, and 80 compounds ran-
domly selected from MetaboMiner's spectral library. Spectral 
noise was introduced via random (10%) peak deletion and 
random chemical shift changes within ± 0.01 ppm for each 1H 
chemical shift, and within ± 0.05 ppm for each 13C chemical 
shift. Compound identification was based on minimal signa-
tures using the adaptive threshold method. The F-measures 
were averaged over 50 iterations.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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gated the performance of the minimal signature (MS)
method versus the adaptive threshold method under dif-
ferent types of spectral noise. As an additional compari-
son, the percentage match (PM) method was also
included. As shown in Figure 5, the MS method per-
formed consistently better than the PM method when
missing peak and chemical shift variations are present.
The adaptive threshold method appears to be most effec-
Table 1: Performance evaluation using HSQC data collected at pH ~7.2.
Method Sample # Cmpds #Correctly Identified (TP) FN FP Precision (%) Recall (%) F score
MetaboMiner-sp A 27 21 6 6 77.8 77.8 77.8
MetaboMiner-all A 27 15 12 8 65.2 55.6 60.0
HMDB A 27 8 19 19 29.7 29.7 29.7
MMCD A 27 8 19 6 57.1 29.7 39.1
BMRB A 27 6 21 21 22.2 22.2 22.2
PRIMe A 27 14 13 6 70.0 51.9 59.6
MetaboMiner-sp B 21 16 5 5 76.2 76.2 76.2
MetaboMiner-all B 21 9 12 0 100 42.9 60.0
HMDB B 21 1 20 20 4.8 4.8 4.8
MMCD B 21 0 21 0 0 0 0
BMRB B 21 1 20 20 4.8 4.8 4.8
PRIMe B 21 6 15 4 60.0 28.6 38.7
MetaboMiner-sp C 24 22 2 2 91.7 91.7 91.7
MetaboMiner-all C 24 16 8 3 84.2 66.7 74.4
HMDB C 24 9 15 15 37.5 37.5 37.5
MMCD C 24 2 22 0 100 7.4 13.8
BMRB C 24 3 21 21 12.5 12.5 12.5
PRIMe C 24 8 16 5 61.5 33.3 43.2
MetaboMiner-sp D 35 29 6 6 82.9 82.9 82.9
MetaboMiner-all D 35 16 19 7 69.6 45.7 55.2
HMDB D 35 9 26 26 25.7 25.7 25.7
MMCD D 35 4 31 3 57.1 11.4 19.0
BMRB D 35 7 28 28 20.0 20.0 20.0
PRIMe D 35 14 21 5 73.7 40.0 51.8
Samples A, B, and C are synthetic cocktail mixtures and sample D is a plasma sample.
(Annotation: MetaboMiner-sp = searched using the biofluid-specific library; MetaboMiner-all = searched using the entire spectral library; TP = true 
positives; FN = false negatives; FP = false positives).
Table 2: Performance evaluation using TOCSY data collected at pH ~7.2. 
Method Sample # Cmpds # Correctly Identified (TP) FN FP Precision (%) Recall (%) F score
MetaboMiner-sp A 27 23 4 4 85.2 85.2 85.2
MetaboMiner-all A 27 21 6 6 77.8 77.8 77.8
HMDB A 27 2 25 25 7.4 7.4 7.4
MMCD A 27 1 26 26 3.7 3.7 3.7
MetaboMiner-sp B 21 16 5 5 76.2 76.2 76.2
MetaboMiner-all B 21 12 9 2 85.7 57.1 68.5
HMDB B 21 2 19 19 9.5 9.5 9.5
MMCD B 21 2 19 19 9.5 9.5 9.5
MetaboMiner-sp C 24 17 7 7 70.8 70.8 70.8
MetaboMiner-all C 24 15 9 8 65.2 62.5 63.8
HMDB C 24 4 20 20 16.7 16.7 16.7
MMCD C 24 2 22 22 8.3 8.3 8.3
MetaboMiner-sp D 35 30 5 5 85.7 85.7 85.7
MetaboMiner-all D 35 23 12 12 65.7 65.7 65.7
HMDB D 35 3 32 32 8.6 8.6 8.6
MMCD D 35 2 33 33 5.7 5.7 5.7
Samples A, B, and C are synthetic cocktail mixtures and sample D is a plasma sample.
(Annotation: MetaboMiner-sp = searched using the biofluid-specific library; MetaboMiner-all = searched using the entire spectral library; TP = true 
positives; FN = false negatives; FP = false positives).BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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tive for data exhibiting large chemical shift variations.
When chemical shift variation is negligible, as in the test
with missing peak data, this method performs exactly the
same as the fixed threshold method.
The utility of different NMR data types was also investi-
gated using synthetic spectra of increasing complexity. As
illustrated in Figure 6, HSQC, TOCSY and 13C-based
methods worked very well over the full range of com-
pound mixtures. The number of compounds in the query
mixture has very little effect on their overall performance.
The slight increases in F scores with increasing spectral
complexity are not statistically significant. In general,
MetaboMiner's performance for compound identification
was best using the HSQC dataset. It is also apparent that
the minimal signature method favours compound identi-
fication with HSQC spectra as these spectra tend to have
more unique peaks than other types of NMR spectra. Also
evident from Figure 6 is the fact that MetaboMiner's per-
formance using 1D 1H data, alone, is the poorest. In con-
trast to the 1H spectra (both 1D and 2D), it is quite clear
that 13C chemical shifts (even in 1D spectra) can provide
sufficient information for robust compound identifica-
tion. This is mainly due to the much wider chemical shift
dispersion (0~200 ppm) seen in 13C spectra compared to
1H spectra. Most 13C chemical shifts remain unique even
in mixtures of 162 compounds.
While 13C spectra (1D and 2D) provide excellent data sets
for compound identification we found that by focusing
on off-diagonal peaks originating from the coupling
between pairs of protons, the utility of TOCSY spectra
could be greatly improved. As indicated in Figure 6,
MetaboMiner's metabolite identification performance
based on TOCSY spectra was better than that based on 1D
13C spectra and was only slightly outperformed by 13C
HSQC data. These results underscore the utility of using
2D spectra in NMR-based compound identification of
complex (>20 compounds) mixtures.
We also assessed MetaboMiner's performance on its own
and against several other web services using eight experi-
mental NMR spectra collected from four different mix-
tures of known composition. As indicated in Tables 1 and
2, the best performance for MetaboMiner was obtained
when a biofluid-specific reference library was used to ana-
lyze TOCSY or HSQC data. On average, MetaboMiner was
able to correctly identify (recall, precision and F-measure)
an average of 81% of the compounds from both TOCSY
and HSQC data. When the entire spectral library (223
TOCSY, 502 HSQC) was used, the performance (F-meas-
ure) decreased by an average of 15%. Among the four web
services evaluated using the same data (Table 1), the
SpinAssign program performs the best (F-measure = 49%)
but this is still about 30% worse than MetaboMiner when
it uses a biofluid-specific library and 15% worse than
MetaboMiner when it uses its entire spectral library. Over-
all, the other web servers did not perform particularly well
with average F-measures of 15–25% for HSQC data and
6–12% for TOCSY data. Both the HMDB and MMCD serv-
ers performed better when analyzing HSQC data than
TOCSY data. The performance for all web servers was
essentially the same regardless of whether "clean" peak
lists (no noise peaks) or "raw" peak lists were used as
input. Note that TOCSY mixture analysis is not currently
supported by either PRIMe or BMRB.
In an effort to understand the influence of pH on the effi-
cacy of compound identification by 2D NMR, we also col-
lected TOCSY and HSQC data at pH 4.2 and pH 8.8. This
is approximately 3 pH units below (and 1.5 pH units
above) the pH at which the spectral library standards were
collected. As seen in Table 3, a significant pH change in
the sample (relative to the pH of the spectral libraries) can
negatively impact the performance of compound identifi-
cation. For instance, at pH 4.2, the F-measure drops by
more than 20% for the HSQC spectra.
Discussion
In this paper, we described the development and assess-
ment of a software tool (MetaboMiner) to facilitate com-
pound identification from 2D NMR spectra of biofluids or
small molecule mixtures. We first created a series of
"clean" spectral reference libraries based on publicly avail-
Table 3: Performance evaluation of MetaboMiner under different pH conditions.
Sample # Cmpds NMR Exp. pH # Correctly Identified (TP) FN FP Precision (%) Recall (%) F score
A 27 HSQC 4.2 15 12 12 55.6 55.6 55.6
A 27 HSQC 7.2 21 6 6 77.8 77.8 77.8
A 27 TOCSY 4.2 21 6 6 77.8 77.8 77.8
A 27 TOCSY 7.2 23 4 4 85.2 85.2 85.2
D 35 HSQC 7.3 29 6 6 82.9 82.9 82.9
D 35 HSQC 8.8 24 11 4 85.7 68.6 76.2
D 35 TOCSY 7.3 30 5 5 85.7 85.7 85.7
D 35 TOCSY 8.8 25 10 6 80.6 71.4 75.7
Tests were performed using biofluid-specific library.BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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able spectral databases. Secondly we developed and tested
several algorithms to facilitate robust and automatic peak
processing, peak matching and compound identification.
Finally, we integrated these resources into an easy-to-use
application and evaluated its performance using a variety
of synthetic and real spectra.
MetaboMiner's spectral reference library covers most
NMR-detectable metabolites present in human biofluids
[23]. To improve the reliability of the compound identifi-
cation, the larger spectral library was further partitioned
into three smaller libraries based on the composition of
different biofluids (CSF, plasma and urine). In addition,
we also created "common" libraries for each type of
biofluid that contain the most common or abundant
metabolites found in these biofluids (as ascertained from
previous experience and from data contained in the
HMDB). We found that the creation of biofluid-specific
libraries significantly improved compound identification
by reducing the spectral search space. As indicated in
Tables 1 and 2, a 15% reduction in MetaboMiner's per-
formance occurred if the entire compound library was
used instead of the biofluid-specific "common" library.
For researchers who wish to study other types of biofluids,
MetaboMiner provides intuitive interfaces that allow users
to easily expand and customize their spectral reference
libraries.
Performance Assessment
The performance of MetaboMiner was evaluated using a
variety of synthetic and experimental datasets. In all cases,
our strategies for peak matching and compound identifi-
cation showed robust performance under various noise
(real and synthetic) conditions. Using synthetic data, the
best compound identification performance was ~90% (F-
measure) under moderate noise levels as indicated by Fig-
ure 6. Further inspection of the compound identification
lists showed that the most common problem was the
identification of false positives. In particular, for certain
compounds it is inherently difficult to uniquely identify
them by NMR based on their matched peaks. For example,
the TOCSY peaks of citrate and serine cluster very tightly
around the diagonal. They also overlap with peaks of
other more abundant compound species. As a result, they
are often misidentified. Another source of false positives
comes from the existence of structurally similar com-
pounds such as asparagine/aspartate, inosine/adenosine,
or creatine/creatinine, which have nearly identical NMR
spectral features.
When we assessed the performance of MetaboMiner using
experimentally collected data, the performance was
reduced by ~10% for both TOCSY and HSQC data. Close
examination of the lists of identified compounds as well
as the spectra used in the evaluation indicated two sources
of problems (see Additional File 2). The first relates to the
fact that several compounds known to be in the mixtures
failed to be identified (false negatives). Manual inspection
of the actual spectra (TOCSY or HSQC) indicated that in
every case, no peaks or very weak peaks were visible for
these compounds. These compounds were obviously
below the detection threshold of the instrument. The sec-
ond problem was the existence of several false positives.
Again, manual inspection of the spectra showed that the
false positives were mainly caused by spectral artefacts.
Real spectra [see Additional File 3] can contain a signifi-
cant amount of spectral noise. In the case of TOCSY spec-
tra, most of the automatically picked peaks (>60%) are
from these artefacts. Obviously if cleaner spectra could be
collected or if more manual intervention was used to
eliminate some of the spectral artefacts prior to submit-
ting the data to MetaboMiner, a better performance could
be achieved. In addition, we also observed that some com-
pounds are exquisitely sensitive to small pH variations
such as lactate, uracil and histidine.
Peak uniqueness and the challenges in automated 
compound identification
There are three major challenges facing automatic com-
pound identification for NMR-based metabolomics. The
most common and perhaps the most vexing is the so-
called spectral overlap problem. The spectral complexity
inherent in many biofluids can lead to a large number of
peaks confined to a relatively narrow chemical shift range
(~10 ppm for 1H spectra). With the increased availability
of high-field NMR spectrometers, the problem of spectral
overlap is diminished somewhat for simple biofluids such
as CSF. However, for complex mixtures like plasma, urine,
or tissue extracts, the problem is still quite severe. The sec-
ond challenge in automated compound identification is
the handling of chemical shift changes induced by the var-
iation of pH, temperature, ionic strength, etc. This effect
combined with the first issue makes it difficult to perform
automated compound identification based solely on
chemical shifts. The third challenge in automated com-
pound identification is the low signal-to-noise (S/N) ratio
for the NMR resonances of low abundance compound
species. Consequently, the wide range of metabolite con-
centrations found in many biofluids poses a serious prob-
lem for most automatic peak-picking programs. In
particular, many low intensities peaks are likely to be
missed by most peak picking programs.
To address these challenges we introduced the notion of
"uniqueness" in the reference library in order to deal with
the problem of missing peaks and chemical shift varia-
tions. The uniqueness values were calculated for every
peak based on their relative distances to each other in a
given reference library. Although a finer scale may per-
form better for more complex mixtures, we found that theBMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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use of five levels of uniqueness works well for most situa-
tions. In MetaboMiner, both peak matching and com-
pound identification rely heavily on these uniqueness
values. During peak matching, an adaptive threshold
method was used to adjust the current search threshold to
its maximum uniqueness scope. This approach signifi-
cantly improves MetaboMiner's performance when chem-
ical shift variations are nontrivial. By using an adaptive
threshold method we found the effect of chemical shift
changes or chemical shift drift could be tolerated to a
greater extent. These uniqueness values also allow us to
derive minimal signatures based on a relatively small por-
tion of unique peaks. This approach turned out to be both
robust and flexible since it did not require "stable" spec-
tral patterns. In contrast, the common percentage match
(PM) method weights each peak equally and uses a fixed
threshold for compound identification. This approach
suffers greatly if a nontrivial proportion of peaks are not
matched. Note that the minimal signature method in
MetaboMiner is complemented by authenticity checks
with due consideration of the total matched patterns.
It should be noted that the performance of MetaboMiner
strongly depends on the quality of the upstream spectral
collection and processing work. As a general rule, for opti-
mal performance, the NMR experiments on biofluid mix-
tures should be carried out under the same (or at least
similar) conditions as the conditions used to collect the
spectra for the reference library (i.e. neutral pH). The auto-
matic peak-picking process should be closely monitored
and an iterative approach is recommended in order to
pick up most signals while avoiding obvious spectral
noise. In our testing process, a typical TOCSY spectrum
usually generated 2,000~3,000 peaks with a high propor-
tion of noise peaks. We found that these noisy signals
were handled quite efficiently by MetaboMiner. As a gen-
eral rule, we would suggest that users employ a low
threshold during the peak picking stage for TOCSY spec-
tra. For HSQC spectra, because of the difficulty associated
with detecting and removing noisy signals, we would sug-
gest more manual intervention during the peak picking
process.
Comparison to other spectral analysis software tools
There are several commercial software tools available for
analysing complex metabolite mixtures using NMR.
Chenomx Inc. has developed a commercial bioprofiling
software package called the Chenomx NMR Suite that
allows semi-automated identification of compounds
from 1D 1H NMR spectra. The Chenomx software package
provides an excellent interface for compound identifica-
tion and quantification via a manual peak-fitting process
using a spectra reference library containing 260 com-
pounds [12]. However, the requirement for manual fitting
and analysis leaves the process open to inconsistent inter-
pretation or inconsistent assignment by different individ-
uals. Furthermore, the analysis can take upwards of one
hour per sample and the software is relatively expensive.
Bruker's AMIX (Bruker BioSpin) software is another pow-
erful tool that offers support for compound identification
and quantification for 1D and 2D NMR as well as LC-MS
spectra. It used a method called AutoDROP to facilitate
compound identification and structure verification [30].
The key idea is the systematic decomposition of reference
spectra into spectral patterns of molecular fragments.
Compound identification is based on recognition of such
patterns in the target spectra. However, similar limitations
pertaining to cost, the reliance on manual analysis,
processing time and inconsistent interpretation appear to
apply to AMIX as well.
In addition to these commercial packages there is at least
one other non-commercial system that has been
described. Xi et. al [24] developed a statistical and chemi-
cal model for automatically identifying compounds in
mixtures using 2D COSY spectra. Like MetaboMiner, the
Chenomx NMR Suite and AMIX, Xi et al's method uses a
library of pre-collected NMR spectra to assist with com-
pound identification. These authors reported experimen-
tal results using spectra collected from abalone muscle
and digestive gland extracts. Their method was able to
identify 12 out of 15 amino acids and 6 out of 9 amino
acids as determined with Chenomx's NMR Suite. How-
ever, it appears that this system has a spectral library of
only 19 COSY spectra, so it is very limited in terms of prac-
tical applications.
In addition to these stand-alone, graphically based soft-
ware packages, several metabolomics database websites,
including the HMDB [23], MMCD [25], BMRB [24], and
PRIMe now allow direct querying of their databases using
peak lists obtained from compound mixtures. However,
as web servers they are somewhat limited in their graphic
capabilities and user-interface interactions. In particular,
most of these sites typically return long lists of potentially
matched compounds without a graphic display of the
matched spectra to help users make their decisions. Fur-
ther, most of the servers appear to be designed to handle
single compound or simple mixture queries and are not
optimized for compound identification from complex
biofluid mixtures. This is particularly evident from the
results shown in Tables 1 and 2. The modest performance
for the MMCD and BMRB servers with regard to their han-
dling of HSQC spectra may be partially due to the pH and
solvent differences between the query spectra and their
internal reference spectra (pH 7.0–7.2 in H2O vs. pH 7.4
in D2O), however these pH differences are relatively small
and should not have affected the identification of most
compounds. Furthermore, the fact that the same level of
performance was seen with TOCSY queries where Metab-BMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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oMiner, BMRB and MMCD used the same set of reference
spectra and had the same pH mistmatch suggests that the
performance differences are likely related to algorithmic
robustness. Likewise the relatively good performance of
the PRIMe server is likely due to the fact that it only con-
tains spectra for 80 common compounds. This signifi-
cantly reduces the number of false positives and
somewhat inflates its overall performance.
Overall, MetaboMiner combines many of the useful inter-
active graphic features and high levels of performance of
the stand-alone commercial packages such as Bruker's
AMIX and Chenomx's NMR Suite with the relatively sim-
ple automation or semi-automation seen with NMR-
based metabolomics web servers. Key to MetaboMiner's
success are its large and carefully constructed spectral
libraries, its robust spectral filtering and peak matching
routines, and its use of biofluid-specific spectral libraries
to rationally limit the spectral search space. Given the
extensive testing and the availability of many built-in
tools for spectral manipulation, viewing and annotation
we believe MetaboMiner is well designed and ready for
practical metabolomics applications.
Limitations
MetaboMiner is not without its limitations. In particular,
MetaboMiner does not support compound quantifica-
tion. Efforts are underway to add this functionality to the
program but it appears that quantification via 2D NMR
spectra is intrinsically more difficult and less reliable than
with 1D NMR spectra. Lewis et al. [31] recently described
a quantification method for HSQC spectra using standard
curves calibrated to unique or selected peaks of a given
compound. Quantification by TOCSY still remains diffi-
cult because the magnetization transfer functions for com-
plex spin systems can differ greatly between metabolites.
This can lead to widely different peak intensities. Another
limitation to MetaboMiner (which is also shared by other
NMR analysis programs such as Chenomx's NMR Suite
and Bruker's AMIX) is the fact that MetaboMiner's per-
formance is highly dependent on the spectral quality and
spectral pre-processing of the query (i.e. experimental)
spectra. High signal-to-noise, good phasing, minimal
baseline distortion and the elimination of spectral arte-
facts will always improve the performance. However,
some biofluid samples may be refractory to good spectral
processing or some users may lack sufficient experience/
skill to properly process their spectra. Under these circum-
stances, MetaboMiner's results may prove to be unreliable
or non-reproducible. Overall, the performance for Metab-
oMiner (and even for human experts) degrades as the sig-
nal-to-noise ratio for the peaks of any given compound
drops below 3:1. The lower limit of detection on our 500
MHz instrument for TOCSY data was about 50 mM and
about 100 mM for HSQC data. A third limitation to
MetaboMiner is its limited sensitivity. In particular,
MetaboMiner's exclusive reliance on 2D NMR spectra gen-
erally reduces its sensitivity limit by a factor of ~10 over
what might be detected via 1D spectrum. Obviously the
use of more concentrated samples, longer collection times
or isotopic labelled samples can overcome these prob-
lems, but the trade-off between time, cost and conven-
ience may not always be in MetaboMiner's favour. It is
worth noting that Methods such as ASAP HMQC [32]
now allow very rapid acquisition of 2D NMR data. This
may make the issues of sensitivity and time much less
important, particularly for 2D heteronuclear experiments.
A fourth limitation is that fact that MetaboMiner's spectral
libraries (esp. the TOCSY library) are still missing a
number of important compounds. Efforts are underway
to expand the TOCSY library over the coming months and
the MetaboMiner website will provide periodic reference
spectral updates. Alternately, users are invited (and
encouraged) to add their own spectra to MetaboMiner's
reference libraries. Finally, unlike Chenomx's NMR Suite
and Bruker's AMIX, MetaboMiner's spectral libraries do
not cover a broad range of pH values. As a result, Metabo-
Miner is largely restricted to analyzing spectra from
biofluids or metabolite mixtures that are titrated to pH 7.0
+/- 0.5.
Conclusion
In this paper we have demonstrated that by utilizing the
extra information found in 2D NMR spectra as well as
prior knowledge about the composition of the biofluid
itself, it is possible to semi-automatically identify a signif-
icant number of compounds in complex aqueous mix-
tures (both defined mixtures and biofluids) with excellent
(>80%) accuracy. In particular, the quality and degree of
metabolite identification achieved by MetaboMiner cer-
tainly matches that of what a skilled NMR spectroscopist
could do – but in significantly less time. Overall, we have
shown that by using a comprehensive reference library
coupled with robust algorithms for peak processing, peak
matching and compound identification, the process of
metabolite identification from 2D NMR spectra can be
greatly simplified.
Availability and requirements
Project name: MetaboMiner
Project home page: http://wishart.biology.ualberta.ca/
metabominer
Operating system: Platform independent
Programming language: Java
Other requirements: Java 1.5 or higherBMC Bioinformatics 2008, 9:507 http://www.biomedcentral.com/1471-2105/9/507
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License: GPL
Abbreviations
CSF: cerebrospinal fluid; DSS: 2, 2-Dimethyl-2-silapen-
tane-5-sulfonic acid; GUI: graphic user interface; HPLC:
high performance liquid chromatography; HSQC: hetero-
nuclear single quantum correlation spectroscopy; MS:
mass spectrometry; NMR: nuclear magnetic resonance;
PNG: portable network graphics; ppm: parts per million;
TOCSY: total correlation spectroscopy; TSP: trimethylsi-
lyl-2, 2, 3, 3-tetradeuteropropionic acid; UPLC: ultra-high
performance liquid chromatography; GC-MS: gas chro-
matography mass spectrometry; LC-MS: liquid chroma-
tography mass spectrometry.
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